Watson Files ANDA For Mucinex DM, Gets In Line For Generic Guaifenesin
This article was originally published in The Tan Sheet
Executive Summary
Watson Pharmaceuticals appears to be the first firm to file an abbreviated new drug application with FDA to market a private label version of Reckitt Benckiser's Mucinex DM
You may also be interested in...
Mucinex Patent Ruling Breathes Life Into Watson And Perrigo ANDAs
Watson Pharmaceuticals' success against Reckitt Benckiser's Mucinex patent infringement suit could clear a path for Mucinex equivalents to launch in the first half of 2011.
Mucinex Patent Ruling Breathes Life Into Watson And Perrigo ANDAs
Watson Pharmaceuticals' success against Reckitt Benckiser's Mucinex patent infringement suit could clear a path for Mucinex equivalents to launch in the first half of 2011.
Mucinex Patent Ruling Breathes Life Into Watson And Perrigo ANDAs
Watson Pharmaceuticals' success against Reckitt Benckiser's Mucinex patent infringement suit could clear a path for Mucinex equivalents to launch in the first half of 2011.